GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANG-PD · Mar 31, 2025

American National Group Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001039828-25-000018Insurance
Cash50thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.cash

$7.5B · CORE · VALID

DebtRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_debt

$3.0B · OPTIONAL · NOT_ENOUGH_HISTORY

Net-income growth10thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.net_income

-160.06% · CORE · VALID

Premium growth100thOwn-history percentile · N=20
Evidence method

Yoy · gp.insurance.premiums

138806.25% · CORE · VALID

Revenue growth75thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

136.27% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History51 statesSelf-history eligible
Period transition

What moved in the state?

Cash Decreased
Previous
$11.3B
Current
$7.5B
Delta
-$3.8B
Debt Increased
Previous
$3.0B
Current
$3.0B
Delta
$2.0M
Earnings Growth Decreased
Previous
246.27%
Current
-160.06%
Delta
-406.33%
Premium Growth Increased
Previous
46018.49%
Current
138806.25%
Delta
92787.76%
Revenue Growth Decreased
Previous
235.09%
Current
136.27%
Delta
-98.82%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.